StockNews.AI
CERS
StockNews.AI
193 days

Cerus Corporation to Release Fourth Quarter and Full-Year 2024 Financial Results on February 20, 2025

1. Cerus Corporation will release Q4 and full-year 2024 results on Feb 20, 2025. 2. A conference call will detail financial results and business outlook at 4:30 PM ET. 3. Cerus aims to be the leading global blood products company in pathogen protection. 4. Its INTERCEPT Blood System has FDA approval, enhancing its market position. 5. The red blood cell system is in late-stage clinical development, indicating growth potential.

Earnings
-1.72%Current Return
VS
-0.43%S&P 500
$1.7402/07 08:35 AM EDTEvent Start
$1.7102/10 08:35 AM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results and conference call may boost investor interest, similar to previous earnings calls improving sentiment.

How important is it?

The financial disclosure is critical for investor evaluations and can influence stock performance.

Why Short Term?

The release and corresponding call are imminent and expected to affect price quickly, akin to past earnings reports impacting stock prices.

Related Companies

CERSINTERCEPT
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2024 financial results will be released on Thursday, February 20, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A replay will be available on Cerus’ website and will be available approximately three hours after the call through March 6, 2025. ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is in late-stage clinical development. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn. INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Related News